Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 83687
1. Kim HJ, Lee HJ, Lee DW, Kim JY, Kwon JY, Kim HK, Kim WS, Hwang BY: Anesthetic experience of frontotemporal dementia patient with severe autonomic dysfunction: a case report. Korean J Anesthesiol; 2017 Jun;70(3):356-360

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anesthetic experience of frontotemporal dementia patient with severe autonomic dysfunction: a case report.
  • Anesthetic experience in frontotemporal dementia (FTD) with severe hypotension associated autonomic dysfunction has not yet been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2002 Mar;30(3):497-500 [11990905.001]
  • [Cites] J Cardiovasc Pharmacol. 1980 Jul-Aug;2(4):367-76 [6156335.001]
  • [Cites] Lancet Neurol. 2003 Nov;2(11):669-76 [14572735.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):588-95 [11529214.001]
  • [Cites] Baillieres Clin Neurol. 1992 Nov;1(3):559-82 [1344203.001]
  • [Cites] Neurology. 1998 Dec;51(6):1760-2 [9855544.001]
  • [Cites] J Alzheimers Dis. 2014;42(3):1041-6 [25024313.001]
  • [Cites] J Clin Anesth. 2016 May;30:46-50 [27041263.001]
  • [Cites] Ann Intern Med. 2002 Nov 5;137(9):753-63 [12416949.001]
  • [Cites] Anesthesiology. 2012 Jan;116(1):205-15 [22143168.001]
  • [Cites] Neurologia. 2014 Mar;29(2):76-85 [23601757.001]
  • [Cites] Can J Anaesth. 2004 Feb;51(2):169-72 [14766695.001]
  • [Cites] Circulation. 1997 Mar 4;95(5):1122-5 [9054839.001]
  • [Cites] Brain. 1967 Dec;90(4):725-46 [6075807.001]
  • (PMID = 28580089.001).
  • [ISSN] 2005-6419
  • [Journal-full-title] Korean journal of anesthesiology
  • [ISO-abbreviation] Korean J Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Autonomic nervous system disease / Frontotemporal dementia / Hypotension / Vasopressins
  •  go-up   go-down


2. Zmudka JA, Sérot JM, Dao S, Sorel C, Macaret AS, Balédent O: Specific Effects of Anti-Hypertensive Treatment in an Older Patient with Dementia. Open Neurol J; 2017;11:15-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific Effects of Anti-Hypertensive Treatment in an Older Patient with Dementia.
  • Dementia is one of the most common health problems in the world.
  • Alzheimer's disease (AD) is the most common form of dementia.
  • The relation between blood pressure (BP) and dementia has been the subject of numerous epidemiological studies, midlife HT is a risk factor for dementia and AD [3-7] but the association between HT and risk of dementia is lower in the older population [8].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Aging. 2000 Jan-Feb;21(1):49-55 [10794848.001]
  • [Cites] Lancet. 1996 Apr 27;347(9009):1141-5 [8609748.001]
  • [Cites] Can Fam Physician. 2013 Jan;59(1):19-21, 22-4 [23341648.001]
  • [Cites] Rev Med Interne. 2003 Oct;24 Suppl 3:283s-287s [14710445.001]
  • [Cites] Dement Geriatr Cogn Disord. 2016;41(5-6):314-23 [27398980.001]
  • [Cites] Am J Epidemiol. 2011 Mar 15;173(6):676-82 [21330339.001]
  • [Cites] J Hypertens. 2013 Sep;31(9):1731-68 [24029863.001]
  • [Cites] JAMA. 1963 Sep 21;185:914-9 [14044222.001]
  • [Cites] Hypertension. 2012 Apr;59(4):796-801 [22331381.001]
  • [Cites] J Nutr Health Aging. 2005;9(2):106-11 [15791354.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Oct;14(10):858-65 [10521885.001]
  • [Cites] J Alzheimers Dis. 2012;32(3):609-21 [22810098.001]
  • [Cites] Lancet Neurol. 2006 Sep;5(9):735-41 [16914401.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;31(2):152-7 [21335972.001]
  • [Cites] Ann Intern Med. 1990 Dec 15;113(12):941-8 [2240918.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;31(6):460-6 [21791923.001]
  • [Cites] Gerontologist. 1969 Autumn;9(3):179-86 [5349366.001]
  • [Cites] J Magn Reson Imaging. 2006 Nov;24(5):995-1004 [17024656.001]
  • [Cites] J Am Geriatr Soc. 2002 Aug;50(8):1431-8 [12165002.001]
  • [Cites] Dement Geriatr Cogn Disord. 2010;30(5):440-8 [21109737.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28567135.001).
  • [ISSN] 1874-205X
  • [Journal-full-title] The open neurology journal
  • [ISO-abbreviation] Open Neurol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Asprin / Cerebral blood flow / Dementia / Hypertension / MRI / Stroke
  •  go-up   go-down


3. Moretti R, Caruso P, Dal Ben M, Conti C, Gazzin S, Tiribelli C: Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. Front Aging Neurosci; 2017;9:169

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia.
  • Dementia is a worldwide health problem which affects millions of patients; Alzheimer's disease (AD) and subcortical vascular dementia (sVAD) are the two most frequent forms of its presentation.
  • The statistical models we employed, with regression models built, and adjustments for biochemical, demographic and neuropsychiatric scores, confirmed the association between the three measures (folate decrease, hyperhomocysteinemia and vitamin D decrease) and dementia, more pronounced in sVAD than in AD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Neurology. 2014 Apr 29;82(17 ):1529-35 [24682969.001]
  • [Cites] Eur J Biochem. 2002 Jun;269(12):3014-22 [12071966.001]
  • [Cites] Age Ageing. 2014 Sep;43(5):592-5 [25074538.001]
  • [Cites] Front Neuroendocrinol. 2013 Jan;34(1):47-64 [22796576.001]
  • [Cites] J Inflamm Res. 2016 Apr 27;9:51-7 [27175089.001]
  • [Cites] Neural Plast. 2016;2016:5076740 [26881113.001]
  • [Cites] Am J Clin Nutr. 2013 May;97(5):1004-13 [23485413.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H289-96 [18487433.001]
  • [Cites] Biochim Biophys Acta. 2016 May;1862(5):1008-17 [26689889.001]
  • [Cites] Int J Mol Sci. 2015 Jun 03;16(6):12560-77 [26047341.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Aug;63(2):394-400 [3013918.001]
  • [Cites] Clin Neurol Neurosurg. 1993 Jun;95(2):81-91 [8344019.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:277-86 [23123365.001]
  • [Cites] PLoS One. 2017 Mar 20;12 (3):e0173731 [28319195.001]
  • [Cites] Am J Clin Nutr. 2000 Aug;72(2):324-32 [10919921.001]
  • [Cites] Clin Interv Aging. 2014 Apr 02;9:559-68 [24729696.001]
  • [Cites] Inflamm Res. 2014 Oct;63(10):803-19 [25048990.001]
  • [Cites] Curr Drug Metab. 2002 Apr;3(2):175-87 [12003349.001]
  • [Cites] Neurology. 1994 Dec;44(12):2308-14 [7991117.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] CNS Neurosci Ther. 2013 Mar;19(3):170-7 [23279934.001]
  • [Cites] Am J Clin Nutr. 2016 Sep;104(3):790-6 [27534645.001]
  • [Cites] Nat Rev Neurol. 2011 Mar;7(3):137-52 [21304480.001]
  • [Cites] Front Aging Neurosci. 2017 Mar 30;9:88 [28424613.001]
  • [Cites] AJR Am J Roentgenol. 1987 Aug;149(2):351-6 [3496763.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8351-8 [14660564.001]
  • [Cites] Biomark Res. 2015 Sep 04;3:24 [26346508.001]
  • [Cites] Diabetes Care. 2011 Feb;34(2):454-8 [20978098.001]
  • [Cites] Atherosclerosis. 2013 Jun;228(2):295-305 [23497786.001]
  • [Cites] Lipids Health Dis. 2014 Aug 21;13:134 [25142226.001]
  • [Cites] Biochim Biophys Acta. 2016 May;1862(5):887-900 [26705676.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):451-61 [26890771.001]
  • [Cites] J Steroid Biochem Mol Biol. 2015 Apr;148:305-9 [25448739.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2015-22 [12387654.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16810-5 [17942703.001]
  • [Cites] J Stroke. 2014 Jan;16(1):18-26 [24741561.001]
  • [Cites] Eur J Neurol. 2015 Jan;22(1):106-15, e6-7 [25117780.001]
  • [Cites] Stroke. 2015 Jan;46(1):248-51 [25424481.001]
  • [Cites] Curr Gerontol Geriatr Res. 2011;2011:263507 [21547149.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 2):H1751-8 [9139959.001]
  • [Cites] J Neurol Sci. 2015 Dec 15;359(1-2):108-11 [26671097.001]
  • [Cites] J Thromb Haemost. 2016 Jul;14 (7):1442-52 [27090576.001]
  • [Cites] Neuroscience. 2014 May 30;268:1-9 [24607320.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):557-60 [15225838.001]
  • [Cites] Neurology. 2000 Dec 12;55(11):1621-6 [11113214.001]
  • [Cites] J Neurol Sci. 2012 Nov 15;322(1-2):2-10 [22575403.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):425-8 [12849121.001]
  • [Cites] DNA Cell Biol. 2007 Oct;26(10):737-44 [17764386.001]
  • [Cites] Arch Neurol. 2002 May;59(5):787-93 [12020261.001]
  • [Cites] Sci Rep. 2016 Sep 29;6:34403 [27679973.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Oct 08;(4):CD004514 [18843658.001]
  • [Cites] J Inherit Metab Dis. 2011 Feb;34(1):75-81 [20814827.001]
  • [Cites] Ann Lab Med. 2013 Nov;33(6):393-400 [24205486.001]
  • [Cites] J Cell Biochem. 1996 Nov 1;63(2):199-206 [8913871.001]
  • [Cites] Mediators Inflamm. 2015;2015:460310 [25741130.001]
  • [Cites] Circulation. 2005 Apr 5;111(13):1666-71 [15795327.001]
  • [Cites] Med Monatsschr Pharm. 2006 Aug;29(8):291-302 [16927597.001]
  • [Cites] Front Aging Neurosci. 2013 Apr 10;5:17 [23596414.001]
  • [Cites] Gerontologist. 1989 Jun;29(3):328-32 [2759453.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Mol Neurobiol. 2016 Nov;53(9):5876-5892 [26497037.001]
  • [Cites] Neuromolecular Med. 2010 Jun;12(2):193-204 [19579016.001]
  • [Cites] J Intern Med. 2007 Aug;262(2):244-53 [17645592.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Neuroscience. 2005;133(4):925-35 [15916860.001]
  • [Cites] Neurochem Res. 2003 Feb;28(2):259-69 [12608699.001]
  • [Cites] Curr Med Chem. 2014;21(32):3662-72 [25005183.001]
  • [Cites] Stroke. 2009 May;40(5):e331-9 [19182083.001]
  • [Cites] Acta Neurol Scand. 2006 Feb;113(2):87-91 [16411968.001]
  • [Cites] Behav Brain Res. 2013 Apr 1;242:47-53 [23275047.001]
  • [Cites] J Neurol Sci. 1993 Jan;114(1):7-12 [8433101.001]
  • [Cites] Am J Clin Nutr. 2017 Apr;105(4):936-943 [28202477.001]
  • [Cites] Alzheimer Dis Assoc Disord. 1991 Summer;5(2):91-102 [2059412.001]
  • [Cites] Behav Brain Res. 2005 Jun 20;161(2):306-12 [15922058.001]
  • [Cites] J Leukoc Biol. 2010 May;87(5):779-89 [20130219.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Am J Pathol. 1969 Jul;56(1):111-28 [5792556.001]
  • [Cites] N Engl J Med. 2002 Feb 14;346(7):476-83 [11844848.001]
  • [Cites] Diabetes Care. 2008 Aug;31(8):1473-8 [18540046.001]
  • [Cites] Acta Neurol Scand. 1987 Apr;75(4):262-70 [3591276.001]
  • [Cites] Front Cell Neurosci. 2013 Jan 17;6:66 [23335880.001]
  • [Cites] Alzheimers Dement. 2014 May;10(3):296-302 [23871764.001]
  • [Cites] Neurol Sci. 2013 Aug;34(8):1453-8 [23250517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5923-8 [9159176.001]
  • [Cites] Acta Neurol Scand. 1991 Mar;83(3):187-93 [2031453.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E125-32 [15367398.001]
  • [Cites] Circulation. 2009 Aug 25;120(8):687-98 [19667238.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):98-108 [11150325.001]
  • [Cites] PLoS One. 2013 Aug 09;8(8):e71593 [23951200.001]
  • [Cites] Circulation. 2011 Oct 25;124(17):1808-10 [22025636.001]
  • [Cites] Annu Rev Nutr. 2016 Jul 17;36:211-39 [27431367.001]
  • [Cites] FEBS Lett. 2006 May 29;580(13):2994-3005 [16697371.001]
  • [Cites] J Am Geriatr Soc. 2014 Oct;62(10 ):1993-4 [25333541.001]
  • [Cites] Endocrinology. 2012 May;153(5):2420-35 [22408173.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • [Cites] Neurology. 1992 Mar;42(3 Pt 1):473-80 [1549205.001]
  • [Cites] Neurobiol Aging. 2000 Mar-Apr;21(2):161-9 [10867201.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1153-61 [14528310.001]
  • [Cites] Neurochem Int. 2003 Nov;43(6):597-602 [12820989.001]
  • (PMID = 28611659.001).
  • [ISSN] 1663-4365
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; AD / homocysteine / inflammation / neurodegeneration / sVAD / vitamin D-OH 25
  •  go-up   go-down


Advertisement
4. Yu H, Chen T, Zhou L, Tang J: Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats. Med Sci Monit; 2017 Feb 15;23:818-825
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats.
  • However, whether 5-HT6R is involved in the development of vascular dementia (VD) remains unclear.
  • [MeSH-major] Dementia, Vascular / drug therapy. Receptors, Serotonin / metabolism. Serotonin Receptor Agonists / pharmacology
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Brain / physiopathology. Disease Models, Animal. Hippocampus / metabolism. Learning. Male. Maze Learning / drug effects. Memory / drug effects. Memory / physiology. Neurotransmitter Agents / agonists. Neurotransmitter Agents / metabolism. Random Allocation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Neurol Neurosci. 2015;37:78-92 [26587900.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2011 May;26(3):169-83 [21429956.001]
  • [Cites] Curr Neuropharmacol. 2015;13(6):793-801 [26630957.001]
  • [Cites] Clin Interv Aging. 2015 Oct 23;10:1695-704 [26604717.001]
  • [Cites] Neural Regen Res. 2015 Sep;10(9):1418-20 [26604901.001]
  • [Cites] Expert Rev Neurother. 2014 Sep;14(9):1067-77 [25105544.001]
  • [Cites] Biol Pharm Bull. 1997 Apr;20(4):349-53 [9145208.001]
  • [Cites] Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):79-82 [25202788.001]
  • [Cites] Neurotherapeutics. 2011 Jul;8(3):361-73 [21556678.001]
  • [Cites] Evid Based Complement Alternat Med. 2014;2014:294103 [25024727.001]
  • [Cites] Curr Neurovasc Res. 2014 May;11(2):94-106 [24597602.001]
  • [Cites] J Neurol Sci. 2014 Dec 15;347(1-2):66-77 [25266713.001]
  • [Cites] Neurosci Lett. 2015 Feb 5;587:113-9 [25534501.001]
  • [Cites] Neurol Sci. 2012 Feb;33(1):39-43 [21647626.001]
  • [Cites] Cochrane Database Syst Rev. 2015 Mar 03;(3):CD009444 [25734590.001]
  • [Cites] Neuropathology. 2016 Apr;36(2):115-24 [26607405.001]
  • [Cites] Cell Physiol Biochem. 2013;31(6):761-77 [23735822.001]
  • [Cites] Lancet. 2015 Oct 24;386(10004):1698-706 [26595643.001]
  • [Cites] Curr Pharm Des. 2014;20(2):161-71 [23701539.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2013 Aug;22(6):841-5 [22784820.001]
  • [Cites] Wiad Lek. 2014;67(2 Pt 2):161-5 [25796815.001]
  • [Cites] Pharmacol Biochem Behav. 2016 Jan;140:1-7 [26549214.001]
  • (PMID = 28196966.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Receptors, Serotonin; 0 / Serotonin Receptor Agonists; 0 / serotonin 6 receptor
  •  go-up   go-down


5. Stocks SJ, Kontopantelis E, Webb RT, Avery AJ, Burns A, Ashcroft DM: Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice. Drug Saf; 2017 Aug;40(8):679-692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice.
  • INTRODUCTION: Policy interventions to address inappropriate prescribing of antipsychotic drugs to older people diagnosed with dementia are commonplace.
  • METHODS: We analysed routinely collected primary-care data from 111,346 patients attending one of 689 general practices contributing to the Clinical Practice Research Datalink to describe the temporal changes in the prescribing of antipsychotic drugs to patients aged 65 years or over diagnosed with dementia without a concomitant psychosis diagnosis from 2001 to 2014 using an interrupted time series and a before-and-after design.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2007 Jun 5;146(11):775-86 [17548409.001]
  • [Cites] BMJ Open. 2016 Sep 20;6(9):e009882 [27650756.001]
  • [Cites] BMJ. 2014 Nov 03;349:g6420 [25368388.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] Drug Saf. 2015 Jun;38(6):565-75 [25968811.001]
  • [Cites] BMJ. 2015 Nov 03;351:h5501 [26537416.001]
  • [Cites] PLoS One. 2016 Feb 26;11(2):e0146715 [26918439.001]
  • [Cites] Arch Intern Med. 2008 May 26;168(10):1090-6 [18504337.001]
  • [Cites] PLoS One. 2014 Jun 18;9(6):e99825 [24941260.001]
  • [Cites] JAMA Psychiatry. 2015 May;72 (5):438-45 [25786075.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14 ):1448-54 [15459308.001]
  • [Cites] J Clin Psychopharmacol. 2016 Aug;36(4):308-13 [27300250.001]
  • [Cites] CNS Drugs. 2016 Nov;30(11):1097-1109 [27423216.001]
  • [Cites] CMAJ. 2008 Aug 26;179(5):438-46 [18725616.001]
  • [Cites] J Public Health (Oxf). 2015 Jun;37(2):346-52 [24681910.001]
  • [Cites] Drug Saf. 2015 Jul;38(7):671-82 [26100143.001]
  • [Cites] BMJ. 2015 Jun 09;350:h2750 [26058820.001]
  • [Cites] BMJ Open. 2013 Aug 02;3(8):null [23913774.001]
  • [Cites] Am J Psychiatry. 2012 Jan;169(1):71-9 [22193526.001]
  • [Cites] CMAJ. 2007 Feb 27;176(5):627-32 [17325327.001]
  • [Cites] Br J Psychiatry. 2012 Sep;201(3):221-6 [22790679.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Int J Epidemiol. 2015 Jun;44(3):827-36 [26050254.001]
  • [Cites] PLoS One. 2013 Jul 17;8(7):e68976 [23874832.001]
  • [Cites] BMJ. 2011 Feb 10;342:d549 [21310794.001]
  • [Cites] BMJ Open. 2013 Jan 07;3(1):null [23299113.001]
  • (PMID = 28439716.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / DH/ gmpstrc-2012-1
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


6. Rozin SI: Case Series Using Montelukast in Patients with Memory Loss and Dementia. Open Neurol J; 2017;11:7-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case Series Using Montelukast in Patients with Memory Loss and Dementia.
  • Cognitive decline and dementia are a growing problem as the population ages.
  • Neuro-inflammation has been suggested as a cause of dementia [1].
  • This case series of patients in a private Internal Medicine practice between 2013-2014 used Montelukast in patients with various levels of memory impairment and dementia.
  • Patients with dementia were noted by family members to be less agitated, but had no memory improvement at the doses used.
  • Montelukast may be useful to treat memory impairment and dementia.
  • Long term use might act as a prophylactic to prevent dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharm Pharmacol. 2011 Apr;63(4):550-7 [21401607.001]
  • [Cites] Nat Commun. 2015 Oct 27;6:8466 [26506265.001]
  • [Cites] Glia. 2008 Jan 1;56(1):27-37 [17910051.001]
  • [Cites] J Am Geriatr Soc. 2005 Apr;53(4):695-9 [15817019.001]
  • [Cites] Acta Pharmacol Sin. 2006 Dec;27(12):1553-60 [17112408.001]
  • [Cites] Neuroscience. 2010 Nov 24;171(1):284-99 [20813166.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Int J Alzheimers Dis. 2010 Jun 14;2010:null [20798769.001]
  • [Cites] J Immunol. 2011 Sep 1;187(5):2336-45 [21804021.001]
  • [Cites] Eur J Neurosci. 2004 Sep;20(6):1514-24 [15355318.001]
  • [Cites] Neuropharmacology. 2014 Apr;79:707-14 [24456746.001]
  • (PMID = 28567133.001).
  • [ISSN] 1874-205X
  • [Journal-full-title] The open neurology journal
  • [ISO-abbreviation] Open Neurol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Alzheimer’s / Cognitive impairment / Dementia / Memory loss / Montelukast
  •  go-up   go-down


7. Best S, Pavel DG: Treatment of post-anesthesia dementia with perispinal etanercept injection and hyperbaric oxygen therapy: a case report. J Med Case Rep; 2017 Apr 14;11(1):105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of post-anesthesia dementia with perispinal etanercept injection and hyperbaric oxygen therapy: a case report.
  • BACKGROUND: We report on the first case of successful treatment for post-anesthesia dementia with perispinal etanercept injection combined with hyperbaric oxygen therapy.
  • Diagnoses of dementia with major cognitive deficits and aphasia were established.
  • Starting after the first perispinal etanercept injection, our patient began showing progressive improvements.
  • CONCLUSIONS: In this case of dementia and major cognitive disorder post major surgery and anesthesia, the very beneficial effect of combining hyperbaric oxygen therapy with perispinal etanercept is outlined.
  • [MeSH-major] Anesthesia / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Arthroplasty, Replacement, Knee. Dementia / etiology. Etanercept / administration & dosage. Hyperbaric Oxygenation. Postoperative Complications / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anesth Analg. 2011 Sep;113(3):626-33 [21596875.001]
  • [Cites] J Nucl Med. 1994 Sep;35(9):1528-37 [8071705.001]
  • [Cites] Expert Rev Neurother. 2010 Jun;10(6):985-1002 [20518613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20518-22 [21041647.001]
  • [Cites] Neural Plast. 2015;2015:358263 [26221543.001]
  • [Cites] Clin Drug Investig. 2014 May;34(5):361-6 [24647830.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Feb;32(1):40-50 [16409552.001]
  • [Cites] J Nucl Med Technol. 2009 Sep;37(3):191-5 [19692453.001]
  • [Cites] J Nucl Med. 1992 Oct;33(10 ):1888-904 [1403163.001]
  • [Cites] Curr Vasc Pharmacol. 2016;14(1):98-105 [26411421.001]
  • [Cites] J Appl Physiol (1985). 2009 Feb;106(2):711-28 [19023021.001]
  • [Cites] Anesthesiology. 2009 Dec;111(6):1365-71 [19934883.001]
  • [Cites] Front Neurosci. 2011 Jan 31;4:272 [21344011.001]
  • [Cites] Stem Cell Res. 2014 May;12(3):638-45 [24642336.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):259-71 [11216525.001]
  • (PMID = 28407792.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; OP401G7OJC / Etanercept
  • [Keywords] NOTNLM ; Case report / Dementia / HBOT / Perispinal etanercept / SPECT
  •  go-up   go-down


8. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, Chang YP: Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One; 2017;12(2):e0171006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.
  • INTRODUCTION: Concerns have been raised regarding the potential association between proton pump inhibitor (PPI) use and dementia.
  • METHODS: Patients initiating PPI therapy between January 1, 2000 and December 31, 2003 without a prior history of dementia were identified from Taiwan's National Health Insurance Research Database.
  • The outcome of interest was all-cause dementia.
  • Cox regression models were applied to estimate the hazard ratio (HR) of dementia.
  • The cumulative PPI dosage stratified by quartiles of defined daily doses and adjusted for baseline disease risk score served as the primary variables compared against no PPI use.
  • RESULTS: We analyzed the data of 15726 participants aged 40 years or older and free of dementia at baseline.
  • PPI users (n = 7863; average follow-up 8.44 years) had a significantly increased risk of dementia over non-PPI users (n = 7863; average follow-up 9.55 years) (adjusted HR [aHR] 1.22; 95% confidence interval: 1.05-1.42).
  • A significant association was observed between cumulative PPI use and risk of dementia (P for trend = .013).
  • Subgroup analysis showed excess frequency of dementia in PPI users diagnosed with depression (aHR 2.73 [1.91-3.89]), hyperlipidemia (aHR 1.81 [1.38-2.38]), ischemic heart disease (aHR 1.55 [1.12-2.14]), and hypertension (aHR 1.54 [1.21-1.95]).
  • CONCLUSIONS: An increased risk for dementia was identified among the Asian PPI users.
  • Cumulative PPI use was significantly associated with dementia.
  • Further investigation into the possible biological mechanisms underlying the relationship between dementia and PPI use is warranted.
  • [MeSH-major] Databases, Factual. Dementia / chemically induced. Dementia / epidemiology. Proton Pump Inhibitors / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019-24 [20623646.001]
  • [Cites] PLoS One. 2015 Jun 10;10(6):e0124653 [26061035.001]
  • [Cites] Aliment Pharmacol Ther. 2012 Nov;36(10):941-9 [23034135.001]
  • [Cites] Aust N Z J Psychiatry. 2001 Dec;35(6):776-81 [11990888.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Oct;64(10):935-51 [18679668.001]
  • [Cites] Arch Neurol. 2004 Aug;61(8):1290-3 [15313849.001]
  • [Cites] Circulation. 2013 Aug 20;128(8):845-53 [23825361.001]
  • [Cites] Br J Nutr. 2012 Dec 14;108(11):1948-61 [23084026.001]
  • [Cites] Biochim Biophys Acta. 1991 Jun 18;1065(2):261-8 [1647821.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Aliment Pharmacol Ther. 1991 Jun;5(3):245-54 [1888824.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1490-6 [17314396.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:9-22 [16700899.001]
  • [Cites] BMJ. 2012 Jan 30;344:e372 [22294756.001]
  • [Cites] J Clin Pharm Ther. 2010 Apr;35(2):125-6 [20456731.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:2-8 [16700898.001]
  • [Cites] Eur J Epidemiol. 2010 Apr;25(4):245-51 [20358262.001]
  • [Cites] Nat Rev Neurol. 2011 May 03;7(6):323-31 [21537355.001]
  • [Cites] PLoS One. 2013;8(3):e58837 [23520537.001]
  • [Cites] JAMA Neurol. 2016 Apr;73(4):410-6 [26882076.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):419-28 [25341874.001]
  • [Cites] Neurology. 2007 Dec 11;69(24):2197-204 [17568013.001]
  • [Cites] J Alzheimers Dis. 2010;19(2):573-89 [20110603.001]
  • [Cites] Psychosom Med. 2013 Jan;75(1):20-9 [23213264.001]
  • [Cites] BMJ. 2008 Jan 5;336(7634):2-3 [18174564.001]
  • [Cites] Alzheimers Dement. 2007 Jul;3(3):186-91 [19595937.001]
  • [Cites] Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329 [23419381.001]
  • [Cites] Medicine (Baltimore). 2016 May;95(21):e3658 [27227925.001]
  • [Cites] JAMA. 2013 Dec 11;310(22):2435-42 [24327038.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Biochem J. 2002 May 1;363(Pt 3):417-29 [11964142.001]
  • [Cites] Arch Gen Psychiatry. 2011 Sep;68(9):970-7 [21893662.001]
  • [Cites] Alzheimers Dement. 2013 Jan;9(1):1-11.e3 [23305821.001]
  • [Cites] J Alzheimers Dis. 2014;42(1):193-200 [24840566.001]
  • [Cites] JAMA Intern Med. 2016 Feb;176(2):238-46 [26752337.001]
  • [Cites] Lancet Neurol. 2006 Nov;5(11):949-60 [17052662.001]
  • [Cites] Ann Neurol. 2015 Aug;78(2):284-94 [25974006.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1857-70 [10806097.001]
  • (PMID = 28199356.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


9. Yabuki Y, Matsuo K, Hirano K, Shinoda Y, Moriguchi S, Fukunaga K: Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice. Pharmacology; 2017;99(3-4):160-171
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice.
  • Memantine, an uncompetitive N-methyl-D-aspartate receptor antagonist, and the cholinesterase inhibitor, donepezil, are approved in most countries for treating moderate-to-severe Alzheimer's disease (AD).
  • Some reports do show memantine/donepezil synergy in ameliorating cognition in AD model animals, but their combined effects on behavioral and psychological symptoms of dementia (BPSD)-like behaviors have not been addressed.
  • [MeSH-major] Cholinesterase Inhibitors / administration & dosage. Dementia / drug therapy. Excitatory Amino Acid Antagonists / administration & dosage. Indans / administration & dosage. Memantine / administration & dosage. Olfactory Bulb / injuries. Piperidines / administration & dosage

  • MedlinePlus Health Information. consumer health - Dementia.
  • Hazardous Substances Data Bank. MEMANTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 S. Karger AG, Basel.
  • (PMID = 28049192.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Excitatory Amino Acid Antagonists; 0 / Indans; 0 / Piperidines; 8SSC91326P / donepezil; W8O17SJF3T / Memantine
  •  go-up   go-down


10. Hewer W, Thomas C: [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice]. Z Gerontol Geriatr; 2017 Feb;50(2):106-114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice].
  • [Transliterated title] Psychopharmakotherapie bei Demenz und Delir : Im Spannungsfeld zwischen Leitlinienempfehlungen und Versorgungspraxis.
  • BACKGROUND AND OBJECTIVES: Psychiatric symptoms in dementia and delirium are associated with a substantially reduced quality of life of patients and their families and often challenging for professionals.
  • MATERIAL AND METHODS: Narrative review with special reference to the German dementia guideline from 2016 and recently published practice guidelines for delirium in old age in German and English language.
  • RESULTS: The indications for use of psychotropic agents, especially antipsychotics, are defined narrowly in the German dementia guideline.
  • Comparable to the German dementia guideline they recommend general medical interventions and nonpharmacological treatment as first line measures and the use of psychotropic agents only under certain conditions.
  • CONCLUSION: The guidelines discussed here advocate well-founded a cautious prescription of psychotropic agents in patients with dementia and delirium.
  • Most notably, however, epidemiological data disclose an unacceptable rate of hazardous overtreatment with psychotropic agents, especially in long-term care of persons with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28124100.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration and dosage / Drug monitoring / Evidence-based medicine / Nonpharmacological treatment
  •  go-up   go-down






Advertisement